Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Eli Lilly & Co (DE:LLY)
XETRA:LLY
Eli Lilly & Co (LLY) Stock Price & Analysis
87 Followers
LLY Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€393.25 - €871.30
Previous Close€868.4
Volume120.00
Average Volume (3M)3.14K
Market Cap
€827.68B
Enterprise Value€849.45B
Total Cash (Recent Filing)$2.59B
Total Debt (Recent Filing)$26.21B
Price to Earnings (P/E)140.8
Beta-0.14
Next Earnings
Aug 08, 2024EPS Estimate
€2.57Next Dividend Ex-Date
Aug 15, 2024Dividend Yield0.51%
Share Statistics
EPS (TTM)6.17
Shares Outstanding950,405,386
10 Day Avg. Volume3,577
30 Day Avg. Volume3,136
Standard Deviation0.09
R-Squared0.01
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)756.52
Price to Sales (P/S)23.05
Price to Cash Flow (P/CF)180.10
P/FCF Ratio867.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue23.64
Enterprise Value/Gross Profit31.41
Enterprise Value/Ebitda91.49
Forecast
1Y Price Target
€851.88Price Target Upside-2.24% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering21
Eli Lilly & Co News
Bulls Say, Bears Say
Bulls Say
AcquisitionsLL Y announced a definitive agreement to acquire Morphic Holding for $57/share in cash, which represents a +79% premium to the July 5th closing price of $31.84.
Market ExpansionKisunla's entry is seen as a positive as it relates to building and expanding the market overall for this generation of Alzheimer’s disease therapeutics.
Product ApprovalLL Y’s donanemab (Kisunla) was approved in patients with early Alzheimer’s disease with mild cognitive impairment and mild dementia.
Bears Say
Clinical DataMORF's lead asset – MORF-057 (oral A4B7 inhibitor) – is coming off proof-of-concept / Ph2a data from its EMERALD-1 study where its clinical benefit / differentiation looked questionable.
Regulatory ChallengesRegulatory challenges could impact the company's ability to bring new products to market.
Sales EstimatesSales estimates are modestly below consensus for 2Q24 largely due to lower expectations for Trulicity.
---
Options Prices
Currently, No data available
---
Ownership Overview
10.91% Insiders
24.62% Mutual Funds
16.47% Other Institutional Investors
48.00% Public Companies and
Individual Investors
LLY FAQ
What was Eli Lilly & Co’s price range in the past 12 months?
Eli Lilly & Co lowest stock price was €393.25 and its highest was €871.30 in the past 12 months.
What is Eli Lilly & Co’s market cap?
Currently, no data Available
When is Eli Lilly & Co’s upcoming earnings report date?
Eli Lilly & Co’s upcoming earnings report date is Aug 08, 2024 which is in 22 days.
How were Eli Lilly & Co’s earnings last quarter?
Eli Lilly & Co released its earnings results on Apr 30, 2024. The company reported €2.369 earnings per share for the quarter, beating the consensus estimate of €2.264 by €0.105.
Is Eli Lilly & Co overvalued?
According to Wall Street analysts Eli Lilly & Co’s price is currently Overvalued.
Does Eli Lilly & Co pay dividends?
Eli Lilly & Co pays a Quarterly dividend of €1.19 which represents an annual dividend yield of 0.51%. See more information on Eli Lilly & Co dividends here
What is Eli Lilly & Co’s EPS estimate?
Eli Lilly & Co’s EPS estimate is €2.57.
How many shares outstanding does Eli Lilly & Co have?
Eli Lilly & Co has 950,405,400 shares outstanding.
What happened to Eli Lilly & Co’s price movement after its last earnings report?
Eli Lilly & Co reported an EPS of €2.369 in its last earnings report, beating expectations of €2.264. Following the earnings report the stock price went up 5.478%.
Which hedge fund is a major shareholder of Eli Lilly & Co?
Among the largest hedge funds holding Eli Lilly & Co’s share is PRIMECAP Management Co. It holds Eli Lilly & Co’s shares valued at 17B.
---
Eli Lilly & Co Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€851.88 (-2.24% Downside)
€851.88 (-2.24% Downside)
Blogger Sentiment
Bullish
DE:LLY Sentiment 84%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $1.6B over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 89%
Bearish news 11%
Bearish news 11%
Technicals
SMA
Positive
20 days / 200 days
Momentum
116.85%
12-Months-Change
Fundamentals
Return on Equity
51.15%
Trailing 12-Months
Asset Growth
20.28%
Trailing 12-Months
Company Description
Eli Lilly & Co
Founded in 1876, Eli Lilly & Co. is a leading healthcare company that manufactures and sells pharmaceutical products worldwide. The company is headquartered in Indianapolis, Indiana.
---
LLY Company Deck
---
LLY Earnings Call
Q1 2024
0:00 / 0:00
---
LLY Revenue Breakdown
84.44% Net product revenue
15.56% Collaboration and other revenue
---
LLY Stock 12 Month Forecast
Average Price Target
€851.88
▼(-2.24% Downside)
Technical Analysis
Best Analysts Covering LLY
1 Year
1 Year Success Rate
28/28 ratings generated profit
1 Year Average Return
+62.22%
reiterated a buy rating 6 days ago
Copying Terence Flynn's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +62.22% per trade.
---